Mentions
Extended reach
Total likes
Video views
AI synopsis
Discussions highlight the groundbreaking nature of the trial, with phrases like 'first time,' 'huge congratulations,' and 'significant and clinically meaningful' to underscore its importance. The use of detailed data, such as the 91.2% survival at 48 months, combined with optimism about future access and treatment, shows deep engagement and recognition of the potential paradigm shift in renal cell carcinoma management.
Most discussions strongly support the study’s findings, emphasizing the significant survival benefits shown in the trial.
The discussions demonstrate high interest, with mentions of the trial’s importance, new advancements, and potential clinical implications.
Participants engage deeply, referencing specific data points, trial details, and expert opinions, indicating thorough discussion.
The widespread recognition, noting it as a breakthrough in renal cancer treatment, signals high impact on the medical community and clinical practices.
The anti–programmed death 1 antibody pembrolizumab was approved by the @US_FDA as adjuvant therapy after surgery for renal-cell carcinoma on the basis of improvements in disease-free survival observed in KEYNOTE-564. Data on overall survival are needed. https://t.co/oVQXvyffL4 https://t.co/e7OBFEK5KM
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma: KEYNOTE-564 @OncoAlert https://t.co/WTeL61qDha https://t.co/ARwvUWuLtG
⚡️ On @NEJM - Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma #KidneyCancer #Immunotherapy @DrChoueiri @tompowles1 @OncoAlert https://t.co/rtrtfd8oZQ https://t.co/vseC4Tr9WN
Original Article: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma (KEYNOTE-564 phase 3 trial) https://t.co/oVQXvyffL4 Editorial: Adjuvant Immunotherapy for Kidney Cancer — A New Strategy with New Challenges https://t.co/jwrTjRL83u #Nephrology https://t.co/OIerKYVNCF
The OncoAlert
3/ Unlike melanoma, RCC has a lower mutation burden. While adjuvant pembrolizumab improved DFS and OS of patients with RCC, a subset of patients still experience RCC recurrence (https://t.co/8hGQjmqZr6). Thus, remains the clinical need to improve outcomes of patients with
This video discusses risk factors, staging, and therapy options for localized renal cell carcinoma, including evidence for adjuvant systemic therapy and recent clinical trial findings on pembrolizumab.
This video reviews the latest evidence on adjuvant pembrolizumab in renal cell carcinoma based on recent NEJM publication. It covers the impact on overall survival, long-term outcomes, safety profile, and clinical…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
【腎細胞癌に対するアジュバント免疫療法】 すこし前の論文ですが議論点が多いのでおさらいがてら
RT @DrChoueiri: 3/ Unlike melanoma, RCC has a lower mutation burden. While adjuvant pembrolizumab improved DFS and OS of patients with RCC,…
RT @DrChoueiri: 3/ Unlike melanoma, RCC has a lower mutation burden. While adjuvant pembrolizumab improved DFS and OS of patients with RCC,…
RT @DrChoueiri: 3/ Unlike melanoma, RCC has a lower mutation burden. While adjuvant pembrolizumab improved DFS and OS of patients with RCC,…
RT @DrChoueiri: 3/ Unlike melanoma, RCC has a lower mutation burden. While adjuvant pembrolizumab improved DFS and OS of patients with RCC,…
RT @DrChoueiri: 3/ Unlike melanoma, RCC has a lower mutation burden. While adjuvant pembrolizumab improved DFS and OS of patients with RCC,…
3/ Unlike melanoma, RCC has a lower mutation burden. While adjuvant pembrolizumab improved DFS and OS of patients with RCC, a subset of patients still experience RCC recurrence (https://t.co/8hGQjmqZr6). Thus, remains the clinical need to improve outcomes of patients with
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @l2presearch: Overall survival with adjuvant pembrolizumab in renal cell carcinoma — the shock of the lightning https://t.co/dEn1M2vG2b
RT @tompowles1: Adjuvant pembrolizumab shows a significant and clinically meaningful OS benefit in intermediate and high risk clear cell r…
RT @NEJM: Original Article: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma (KEYNOTE-564 phase 3 trial) https://t.co/o…
RT @EAU_Uroonco: The RCC Article of the Month highlights the Keynote-564 phase III trial on pembrolizumab as adjuvant therapy for RCC post-…
The RCC Article of the Month highlights the Keynote-564 phase III trial on pembrolizumab as adjuvant therapy for RCC post-nephrectomy. In expert commentary, Dr. Teele Kuusk emphasises the importance of risk-adapted discussions tailored to each patient.
Overall survival with adjuvant pembrolizumab in renal cell carcinoma — the shock of the lightning https://t.co/dEn1M2vG2b
RT @dr_yakupergun: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma: KEYNOTE-564 @OncoAlert https://t.co/WTeL61qDha h…
KEYNOTE-564 Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma | New England Journal of Medicine https://t.co/ZHXHghmtW6
RT @rkalyes1: Hope after the knife for patients with Renal cell Carcinoma! The bigger question is when we would access to these life prolon…
RT @rkalyes1: Hope after the knife for patients with Renal cell Carcinoma! The bigger question is when we would access to these life prolon…
Hope after the knife for patients with Renal cell Carcinoma! The bigger question is when we would access to these life prolonging drugs here in Africa. Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma | New England Journal of Medicine https://t.co/9ZcP4s0Po2?
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma | New England Journal of Medicine https://t.co/zgr8dQadDj
RT @tompowles1: Adjuvant pembrolizumab shows a significant and clinically meaningful OS benefit in intermediate and high risk clear cell r…
RT @nachoduranm: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma | New England Journal of Medicine https://t.co/xMgx98…
RT @NEJM: Original Article: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma (KEYNOTE-564 phase 3 trial) https://t.co/o…
Adjuvant pembrolizumab was associated with a significant and clinically meaningful improvement in overall survival, as compared with placebo, among participants with clear-cell renal-cell carcinoma at increased risk for recurrence after surgery. https://t.co/0UJY9FmxuO https://t.co/7Kfiwh3pIm
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma This study has shown that adjuvant Keytruda (pembrolizumab) was associated with a significant and clinically meaningful improvement in overall survival, as compared with placebo, among participants with https://t.co/svy1GMW49X
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @jeffyoriomd: Glad to have been a small part of this trial showing improved survival in renal cell carcinoma. @TheUSONetwork enrolled o…
RT @NEJM: Original Article: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma (KEYNOTE-564 phase 3 trial) https://t.co/o…
RT @NEJM: Original Article: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma (KEYNOTE-564 phase 3 trial) https://t.co/o…
RT @NEJM: Original Article: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma (KEYNOTE-564 phase 3 trial) https://t.co/o…
RT @NEJM: Original Article: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma (KEYNOTE-564 phase 3 trial) https://t.co/o…
RT @NEJM: Original Article: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma (KEYNOTE-564 phase 3 trial) https://t.co/o…
Original Article: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma (KEYNOTE-564 phase 3 trial) https://t.co/oVQXvyffL4 Editorial: Adjuvant Immunotherapy for Kidney Cancer — A New Strategy with New Challenges https://t.co/jwrTjRL83u #Nephrology https://t.co/OIerKYVNCF
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
Trending on PubMed: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. https://t.co/YKpQzWpNTu
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma | New England Journal of Medicine https://t.co/JoGPmSZLUb
RT @NEJM: The anti–programmed death 1 antibody pembrolizumab was approved by the @US_FDA as adjuvant therapy after surgery for renal-cell c…
RT @NEJM: The anti–programmed death 1 antibody pembrolizumab was approved by the @US_FDA as adjuvant therapy after surgery for renal-cell c…
https://t.co/rrsXXujY3q
RT @NEJM: The anti–programmed death 1 antibody pembrolizumab was approved by the @US_FDA as adjuvant therapy after surgery for renal-cell c…
RT @NEJM: KEYNOTE-564 trial: Improved survival in renal-cell cancer after 1 year of adjuvant therapy was seen with pembrolizumab. At 4 year…
RT @jeffyoriomd: Glad to have been a small part of this trial showing improved survival in renal cell carcinoma. @TheUSONetwork enrolled o…
RT @NEJM: The anti–programmed death 1 antibody pembrolizumab was approved by the @US_FDA as adjuvant therapy after surgery for renal-cell c…
RT @BMJOncology: Extended follow up of an RCT in @NEJM found that adjuvant immunotherapy improves overall survival for renal cell carcinoma…
RT @NEJM: The anti–programmed death 1 antibody pembrolizumab was approved by the @US_FDA as adjuvant therapy after surgery for renal-cell c…
RT @NEJM: The anti–programmed death 1 antibody pembrolizumab was approved by the @US_FDA as adjuvant therapy after surgery for renal-cell c…
RT @NEJM: The anti–programmed death 1 antibody pembrolizumab was approved by the @US_FDA as adjuvant therapy after surgery for renal-cell c…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @NEJM: The anti–programmed death 1 antibody pembrolizumab was approved by the @US_FDA as adjuvant therapy after surgery for renal-cell c…
RT @NEJM: The anti–programmed death 1 antibody pembrolizumab was approved by the @US_FDA as adjuvant therapy after surgery for renal-cell c…
RT @NEJM: KEYNOTE-564 trial: Improved survival in renal-cell cancer after 1 year of adjuvant therapy was seen with pembrolizumab. At 4 year…
RT @NEJM: The anti–programmed death 1 antibody pembrolizumab was approved by the @US_FDA as adjuvant therapy after surgery for renal-cell c…
RT @NEJM: The anti–programmed death 1 antibody pembrolizumab was approved by the @US_FDA as adjuvant therapy after surgery for renal-cell c…
RT @NEJM: The anti–programmed death 1 antibody pembrolizumab was approved by the @US_FDA as adjuvant therapy after surgery for renal-cell c…
RT @NEJM: The anti–programmed death 1 antibody pembrolizumab was approved by the @US_FDA as adjuvant therapy after surgery for renal-cell c…
RT @NEJM: The anti–programmed death 1 antibody pembrolizumab was approved by the @US_FDA as adjuvant therapy after surgery for renal-cell c…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @NEJM: The anti–programmed death 1 antibody pembrolizumab was approved by the @US_FDA as adjuvant therapy after surgery for renal-cell c…
RT @NEJM: The anti–programmed death 1 antibody pembrolizumab was approved by the @US_FDA as adjuvant therapy after surgery for renal-cell c…
RT @NEJM: The anti–programmed death 1 antibody pembrolizumab was approved by the @US_FDA as adjuvant therapy after surgery for renal-cell c…
RT @NEJM: The anti–programmed death 1 antibody pembrolizumab was approved by the @US_FDA as adjuvant therapy after surgery for renal-cell c…
RT @NEJM: The anti–programmed death 1 antibody pembrolizumab was approved by the @US_FDA as adjuvant therapy after surgery for renal-cell c…
The anti–programmed death 1 antibody pembrolizumab was approved by the @US_FDA as adjuvant therapy after surgery for renal-cell carcinoma on the basis of improvements in disease-free survival observed in KEYNOTE-564. Data on overall survival are needed. https://t.co/oVQXvyffL4 https://t.co/e7OBFEK5KM
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
https://t.co/L4aLPy8fn3
https://t.co/1lSBs4Gkj5
RT @OncoAlert: The OncoAlert
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma #science #publication #research #publications https://t.co/GwNR7VojzC
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @drenriquegrande: ⚡️ On @NEJM - Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma #KidneyCancer #Immunotherapy @D…
RT @jeffyoriomd: Glad to have been a small part of this trial showing improved survival in renal cell carcinoma. @TheUSONetwork enrolled o…
Glad to have been a small part of this trial showing improved survival in renal cell carcinoma. @TheUSONetwork enrolled over 12% of the patients! @Doshi1G @SarahCannonDocs @TexasOncology https://t.co/DzXtKOGQyb
RT @OncoAlert: The OncoAlert
Adjuvant pembro vs placebo for renal cell carcinoma: Net OS estimate gain at 2 years: 5%. (91% vs 86%) Severe toxicity (G3-4) net increase: 17% (18.6% Vs 1,2%). Placebomumab seems to be still a decent option for many patients and health systems. https://t.co/UVFIuRzI5c
RT @tompowles1: Adjuvant pembrolizumab shows a significant and clinically meaningful OS benefit in intermediate and high risk clear cell r…
RT @drenriquegrande: ⚡️ On @NEJM - Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma #KidneyCancer #Immunotherapy @D…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @tompowles1: Adjuvant pembrolizumab shows a significant and clinically meaningful OS benefit in intermediate and high risk clear cell r…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @OncoAlert: The OncoAlert
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @yekeduz_emre:
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @yekeduz_emre:
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @DrChoueiri: 1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for…
RT @OncoAlert: The OncoAlert
@tompowles1 @DanaFarber @DrChoueiri @QMUL @QMULBartsTheLon @CRUKCOLcentre The results, published in @NEJM, mark the first time an adjuvant therapy has shown this kind of benefit in kidney cancer after 50 years of research. Huge congratulations to the team. https://t.co/sV3vtWeGBE
Overall Survival with Adjuvant #Pembrolizumab in Renal-Cell Carcinoma KEYNOTE-564 https://t.co/JcNbMeaiLb #Cancer
RT @drenriquegrande: ⚡️ On @NEJM - Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma #KidneyCancer #Immunotherapy @D…
RT @drenriquegrande: ⚡️ On @NEJM - Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma #KidneyCancer #Immunotherapy @D…
RT @drenriquegrande: ⚡️ On @NEJM - Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma #KidneyCancer #Immunotherapy @D…
RT @OncoAlert: The OncoAlert
RT @drenriquegrande: ⚡️ On @NEJM - Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma #KidneyCancer #Immunotherapy @D…
RT @nachoduranm: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma | New England Journal of Medicine https://t.co/xMgx98…
RT @drenriquegrande: ⚡️ On @NEJM - Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma #KidneyCancer #Immunotherapy @D…
RT @drenriquegrande: ⚡️ On @NEJM - Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma #KidneyCancer #Immunotherapy @D…
RT @urbano_anido: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma | New England Journal of Medicine https://t.co/ejpQF…
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma | New England Journal of Medicine https://t.co/ejpQFSuEbC
RT @dr_yakupergun: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma: KEYNOTE-564 @OncoAlert https://t.co/WTeL61qDha h…
RT @InnovOncology:
RT @dr_yakupergun: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma: KEYNOTE-564 @OncoAlert https://t.co/WTeL61qDha h…
RT @dralvaropinto: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma | New England Journal of Medicine https://t.co/dCIZ…
RT @OncoAlert: The OncoAlert
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma https://t.co/Rs15bGh2rm Congrats @DrChoueiri and KEYNOTE 564 investigators. "The estimated overall survival at 48 months was 91.2% in the pembrolizumab group, as compared with 86.0% in the placebo group; the
RT @drenriquegrande: ⚡️ On @NEJM - Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma #KidneyCancer #Immunotherapy @D…
RT @OncoAlert: The OncoAlert
RT @dralvaropinto: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma | New England Journal of Medicine https://t.co/dCIZ…
RT @OncoAlert: The OncoAlert
RT @OncoAlert: The OncoAlert
RT @OncoAlert: The OncoAlert
RT @drenriquegrande: ⚡️ On @NEJM - Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma #KidneyCancer #Immunotherapy @D…
RT @OncoAlert: The OncoAlert
RT @OncoAlert: The OncoAlert
The OncoAlert
RT @dr_yakupergun: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma: KEYNOTE-564 @OncoAlert https://t.co/WTeL61qDha h…
RT @drenriquegrande: ⚡️ On @NEJM - Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma #KidneyCancer #Immunotherapy @D…
⚡️ On @NEJM - Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma #KidneyCancer #Immunotherapy @DrChoueiri @tompowles1 @OncoAlert https://t.co/rtrtfd8oZQ https://t.co/vseC4Tr9WN
RT @dralvaropinto: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma | New England Journal of Medicine https://t.co/dCIZ…
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma | New England Journal of Medicine https://t.co/xMgx98TQMo
RT @dr_yakupergun: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma: KEYNOTE-564 @OncoAlert https://t.co/WTeL61qDha h…
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma | New England Journal of Medicine https://t.co/WwKiHKqdMi
RT @dr_yakupergun: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma: KEYNOTE-564 @OncoAlert https://t.co/WTeL61qDha h…
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma | New England Journal of Medicine https://t.co/dCIZAm28sG
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma | New England Journal of Medicine https://t.co/JIMquyRKxv
RT @dr_yakupergun: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma: KEYNOTE-564 @OncoAlert https://t.co/WTeL61qDha h…
RT @dr_yakupergun: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma: KEYNOTE-564 @OncoAlert https://t.co/WTeL61qDha h…
RT @dr_yakupergun: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma: KEYNOTE-564 @OncoAlert https://t.co/WTeL61qDha h…
RT @dr_yakupergun: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma: KEYNOTE-564 @OncoAlert https://t.co/WTeL61qDha h…
RT @dr_yakupergun: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma: KEYNOTE-564 @OncoAlert https://t.co/WTeL61qDha h…
RT @dr_yakupergun: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma: KEYNOTE-564 @OncoAlert https://t.co/WTeL61qDha h…
RT @dr_yakupergun: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma: KEYNOTE-564 @OncoAlert https://t.co/WTeL61qDha h…
RT @dr_yakupergun: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma: KEYNOTE-564 @OncoAlert https://t.co/WTeL61qDha h…
RT @InnovOncology:
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma https://t.co/SJGUTxxNjy
RT @dr_yakupergun: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma: KEYNOTE-564 @OncoAlert https://t.co/WTeL61qDha h…
RT @dr_yakupergun: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma: KEYNOTE-564 @OncoAlert https://t.co/WTeL61qDha h…
RT @dr_yakupergun: Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma: KEYNOTE-564 @OncoAlert https://t.co/WTeL61qDha h…
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma: KEYNOTE-564 @OncoAlert https://t.co/WTeL61qDha https://t.co/ARwvUWuLtG
Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. https://www.nejm.org/doi/full/10.1056/NEJMoa2312695; Cytokines and their side effects ...
2020;38 NEJMoa2312695 (1):6.e1-6.e7. doi:10.1016/j.urolonc.2019.08.011 ... doi:10.1056/ metastatic renal cell cancer (mRCC): data from the carcinoma. N ...
Noch fehlen Biomarker, um unterscheiden zu können, bei welchen Erkrankten mit Nierenzellkarzinom eine ultrakurze, neoadjuvante Therapie mit einem ...
org/doi/full/10.1056/NEJMoa2312695.
... 10.1056/. NEJMoa2312695. 3. Choueiri TK, Tomczak P, Park SH, Venugopal B,. Symeonides S, Hajek J, Ferguson T, Chang YH, Lee JL,. Haas N, Sawrycki P, Sarwar N ...
doi: 10.1056/. NEJMoa2312695]. Over a median follow-up of 9.3 years, kidney failure or renal death occurred in. 3 years in the immediate ART group and. 5 years ...
Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N Engl J Med. 2024; 390:1359–1371. doi: 10.1056/. NEJMoa2312695]. Over a median follow- ...
DOI: 10.1056/NEJMoa2312695. 5. Blank CU, Lucas MW, Scolyer RA, et al.: Neoadjuvant Nivolu- mab and Ipilimumab in Resectable Stage III ...
doi:10.1056/NEJMoa2312695. Newsletter. Stay up to date on recent advances in the multidisciplinary approach to cancer. Subscribe Now ...
doi:10.1056/NEJMoa2312695; FDA approves pembrolizumab for adjuvant treatment of renal cell carcinoma. News release. FDA. November 17, 2021 ...
doi:10.1056/NEJMoa2312695; FDA approves pembrolizumab for adjuvant treatment of renal cell carcinoma. News release. FDA. November 17, 2021 ...
New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2312695. Valeria Vladova ·
doi:10.1056/NEJMoa2312695; Motzer RJ, Russo P, Grünwald V, et al. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell ...
... 10.1056/NEJMoa2312695, keep in mind I was there but I am very new to all of this), we both decided to go through this but as soon it started ...
doi:10.1056/NEJMoa2312695. Download RIS. Articles in this issue. Previous slide. Next slide. about 1 year ago. Video. Dr Voss on Cabozantinib ...
Article of the day❗️Suggested by the Immune Oncology Research Institute Overall Survival with Adjuvant Pembrolizumab in Renal-Cell ...
doi:10.1056/NEJMoa2312695; FDA approves pembrolizumab for adjuvant treatment of renal cell carcinoma. FDA. November 17, 2021. Accessed May 30 ...
Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N Engl J Med 2024; 390:1359–1371. doi: 10.1056/NEJMoa2312695].
doi:10.1056/NEJMoa2312695. 2. Voss MH, Motzer RJ. Adjuvant immunotherapy for kidney cancer — a new strategy with new challenges. N Engl J Med ...
... 10.1056/NEJMoa2312695) publiziert wurden. Pembrolizumab ist in dieser Indikation aufgrund von positiven Zwischenergebnissen bereits ...
... 10.1056/NEJMoa2312695](https://www.nejm.org/doi/full/10.1056 ... org/doi/full/10.1056/NEJMoa23126 95. No photo description available ...
doi:10.1056/NEJMoa2312695. Voss MH, Motzer RJ. Adjuvant immunotherapy for kidney cancer — a new strategy with new challenges. N Engl J Med ...
doi: 10.1056/NEJMoa2312695. PMID: 38631003. 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不 ...
doi:10.1056/NEJMoa2312695. Newsletter. Stay up to date on recent advances in the multidisciplinary approach to cancer. Subscribe Now ...
10.1056/NEJMoa2312695. Method of Research. Randomized controlled/clinical trial. Article Title. Overall Survival with Adjuvant Pembrolizumab in ...
doi.org/10.1056/NEJMoa2312695. Be the first to rate this article. Posted in: Drug Trial News | Medical Condition News. Comments (0). Download ...
... 10.1056/NEJMoa2312695 KEYNOTE-564 (RCT, 腎切除後高復發性的局部clear cell RCC, 平均追蹤57.2 個月，n= 994) 的第三次期中分析發現Pembrolizumab ...
org/doi/full/10.1056/NEJMoa2312695 KEYNOTE-564 (RCT, 腎切除後高復發性的局部 clear cell RCC, 平均追蹤57.2 個月，n= 994) 的第三次期中分析發現 ...
N
YE
EG
O
TM
J
YP
DN
FS
SF
SC
IO
A
RC
Y
EU
LL
H
DM
AM
RL
IP
DI
E
DP
BO
BD
BK
JL
DR
GK
M
村製
WT
AS
PT
SC
SF
Aا
GM
FR
旅T
RC
TP
I
R
TN
D
TG
NN
AP
JN
TL
JR
AA
KE
AD
RY
KA
UU
MM
A
W
IS
J
DD
UA
GV
A
A
ZI
RM
GM
JM
BW
LP
C
RH
AZ
KM
FB
DM
HG
AP
OA
K
NV
IC
O
LU
CD
S
LP
IP
S
ER
KP
MD
OD
E
BM
CV
SJ
C
FM
OB
CF
DS
PQ
OO
CD
DG
TP
DG
WF
DU
AD
DA
EY
M
PS
YÜ
EA
ID
AP
HT
CR
ÁP
JK
S
EM
KA
NR
GF
MC
MK
TM
MO
TO
CS
VV
TY